Astellas Pharma and the Yaskawa Electric Corporation have agreed to form a joint venture (JV) that will focus on developing a cell therapy product manufacturing platform.
The JV will leverage a dual-arm robot known as Maholo, developed by Yaskawa subsidiary the Robotic Biology Institute.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The JV provides access to the platform for academic institutions and startups, promoting collaboration and innovation in the cell therapy field.
Following a memorandum of agreement signed in May 2024, the two companies have progressed to a definitive agreement to form the JV, with capital of 4.5bn yen.
Astellas brings its expertise in cell therapy research and development, manufacturing and in the dual-arm robot Maholo.
Astellas will own 60% of the JV while the remainder will be held by Yaskawa.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe establishment of the JV, which is yet to be named, is contingent on pending regulatory approvals and other closing conditions, with a tentative establishment date set for September 2025.
The JV will leverage Maholo to explore a manufacturing process that ensures high precision and reproducibility while optimising the digitised process through AI integration.
It will focus on a seamless one-click transfer of the digitalised manufacturing process to other facilities, establishing a cell manufacturing platform that adheres to good manufacturing practice (GMP) standards.
It will also create manufacturing processes for cell therapy product candidates from partners, including academia and startups, and manufacture investigational drugs in GMP-certified facilities.
This collaboration comes on the heels of Astellas Pharma’s May 2024 memorandum of understanding with YASKAWA Electric Corporation to begin discussions on the creation of an innovative cell therapy ecosystem through the integration of pharmaceutical and robotics technologies. In October 2023 Astellas Pharma had signed a memorandum of understanding with BioLabs Global and Mitsui Fudosan to bolster the life sciences sector in various Japanese regions.
Update: The last paragraph was updated to include information on a memorandum of understanding between Astellas Pharma and YASAKAWA.
